Chegg (CHGG)

The stock plunged 39.2% in the premarket action after the online education company reported a cut lowered its revenue outlook, saying current economic conditions are pushing consumers to prioritize “earning over learning”. 

Also Read | US Supreme Court’s Roe v. Wade draft opinion exposes partisan fissures

Logitech (LOGI)

Shares of Logitech slipped 5.3% after reporting a 20% decline in sales from a year earlier, as the manufacturer of computer mice, keyboards and other peripherals faced tough comparisons to a pandemic-induced surge last year.

Also Read | ‘My money is in his hands’: Twitter user worries after seeing Elon Musk makes funny faces

Nutrien (NTR)

Shares of Nutrien surged 4.8% in the premarket trading after reporting a rise in quarterly profit and raising its full-year forecast. The world’s largest fertilizer maker’s results were boosted by surging prices for crop nutrients.

Paramount Global (PARA)

Shares of Paramount Global fell 4.3% in the premarket
despite reporting a quarterly profit that beat market estimates. Revenues stood
below analysts’ forecasts for the media company, amid increasing video
streaming competition and weak ad sales growth.

Also Read | Uyghurs, Rohingyas get special mention in Joe Biden’s Eid greetings

Expedia (EXPE)

Shares of Expedia rose 1.5% in the premarket after it reported a loss of 47 cents per share for the first quarter, but that was less than the analysts’ expectation of 62 cents per share loss. The travel services company’s revenue exceeded estimates, as travel demand remained strong amid concerns about Covid, Ukraine and other factors.

Also Read | Russia plans to annex more of Ukraine in coming days, US official warns

Pfizer (PFE)

Pfizer shares fell 1.3% in the premarket after it reported a first-quarter profit of $1.62 per share, 15 cents per share higher than market estimates. Revenue also beat forecasts. The drugmaker lowered its full-year outlook due to an accounting change.

Also Read | A new America: What happens if Roe v Wade falls

Biogen (BIIB)

Biogen’s stock rose 1% in the premarket trading after it
announced that CEO Michel Vounatsos would be stepping down, but will remain in
the position until a successor is found. In addition, the drugmaker reported a
quarterly profit of $4.38 per share and revenue was in line with estimates.